DE4012894C2 - Pharmaceutical agent for the treatment of disorders of the fat metabolism - Google Patents
Pharmaceutical agent for the treatment of disorders of the fat metabolismInfo
- Publication number
- DE4012894C2 DE4012894C2 DE19904012894 DE4012894A DE4012894C2 DE 4012894 C2 DE4012894 C2 DE 4012894C2 DE 19904012894 DE19904012894 DE 19904012894 DE 4012894 A DE4012894 A DE 4012894A DE 4012894 C2 DE4012894 C2 DE 4012894C2
- Authority
- DE
- Germany
- Prior art keywords
- fish oil
- carnitine
- disorders
- pharmaceutical agent
- fat metabolism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000004060 metabolic process Effects 0.000 title claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 5
- 208000035475 disorder Diseases 0.000 title claims description 5
- 239000008177 pharmaceutical agent Substances 0.000 title claims description 5
- 235000021323 fish oil Nutrition 0.000 claims description 21
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 16
- 229960004203 carnitine Drugs 0.000 claims description 14
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 6
- 235000019197 fats Nutrition 0.000 claims description 5
- 241000251468 Actinopterygii Species 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 5
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 2
- 241000252203 Clupea harengus Species 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 235000019514 herring Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000019513 anchovy Nutrition 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- YQGDEPYYFWUPGO-UHFFFAOYSA-N gamma-amino-beta-hydroxybutyric acid Chemical compound [NH3+]CC(O)CC([O-])=O YQGDEPYYFWUPGO-UHFFFAOYSA-N 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940119224 salmon oil Drugs 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
Die Erfindung betrifft ein oral zu applizierendes pharmazeutisches Mittel zur Behandlung von Störungen des Fettstoffwechsels, insbeson dere der Hyperlipidämie, auf der Grundlage von Fischöl und Carnitin in einem Verhältnis von 1 : 2 bis 10 : 1.The invention relates to a pharmaceutical agent for oral administration Treatment of disorders of fat metabolism, in particular of hyperlipidemia, based on fish oil and Carnitine in a ratio of 1: 2 to 10: 1.
Arteriosklerose ist nach Herzkrankheiten und Krebserkran kungen eine der Haupttodesursachen bei Menschen. Ein Risikofaktor für die Erkrankung an Arteriosklerose ist eine erhöhte Menge an Serumlipiden und Lipoproteinen, so daß eine Senkung der Serumlipid- und Lipoproteinspiegel für die Therapie wichtig ist.Atherosclerosis is after heart disease and cancer crane one of the main causes of death in humans. A Risk factor for arteriosclerosis disease an increased amount of serum lipids and lipoproteins, so that a decrease in serum lipid and lipoprotein levels is important for therapy.
Als Lipidsenker kommen neben den seit langem bekannten Chemotherapeutika in neuerer Zeit Produkte zur Anwendung, die sich in natürlichen Materialien finden. In diesem Zusammenhang sind in erster Linie ungesättigte Fettsäuren zu nennen.As lipid-lowering agents come alongside those that have been known for a long time Chemotherapy drugs more recently products for use, that are found in natural materials. In this The connection is primarily unsaturated fatty acids to call.
Die EP-A-86 116 933 beschreibt ein pharinazeutisches Präparat zur Behandlung von Störungen des Fettstoffwech sels, das Knoblauchextrakt und Fischöl enthält. Mit diesem Präparat sollen bei Dosierungen von 2 bis 4 g pro Tag vorteilhafte Ergebnisse erzielt werden.EP-A-86 116 933 describes a pharmaceutical one Preparation for the treatment of disorders of the fat metabolism sels, which contains garlic extract and fish oil. With this The preparation should be used at doses of 2 to 4 g per day advantageous results can be achieved.
Carnitin-(4-Amino-3-hydroxybuttersäuretrimethylbetain), das früher als Vitamin BT bezeichnet wurde, kommt in allen Geweben, insbesondere der quergestreiften Muskula tur vor. Es ist als Transportprotein von Acylgruppen am Fettstoffwechsel beteiligt. Carnitine (4-amino-3-hydroxybutyric acid trimethylbetaine), formerly known as vitamin B T , is found in all tissues, especially the striated muscles. As a transport protein of acyl groups, it is involved in fat metabolism.
Überraschenderweise wurde nun gefunden, daß eine Kombination von Carnitin und Fischöl in der Lage ist, den Serumlipid- und Lipoproteinspiegel stark zu senken.Surprisingly, it has now been found that a combination of carnitine and fish oil is able to reduce the serum lipid and greatly reduce lipoprotein levels.
Gegenstand der vorliegenden Erfindung ist daher ein pharmazeutisches Mittel, das Fischöl und Carnitin in einem Verhältnis von 2 : 1 bis 10 : 1 enthält. Dieses Mittel ist zur Behandlung von Störungen des Fettstoffwechsels und insbesondere der Hyperlipidämie brauchbar.The subject of the present invention is therefore a pharmaceutical agent, the fish oil and carnitine in one Ratio of 2: 1 to 10: 1 contains. This remedy is for Treatment of disorders of fat metabolism and particularly useful for hyperlipidemia.
Fischöl, das erfindungsgemäß zur Anwendung kommen kann, ist in der EP-A-86 116 933 beschrieben. Auf diese Publi kation wird hiermit in vollem Umfang Bezug genommen.Fish oil, which can be used according to the invention, is described in EP-A-86 116 933. On this publi cation is hereby fully referred to.
Fischöl hat einen hohen Gehalt an C18 bis C22-Fettsäuren, insbesondere vom Omega-3-Typ. Dies gilt insbesondere für das Fischöl von Kaltwasserfischen.Fish oil has a high content of C 18 to C 22 fatty acids, especially of the omega-3 type. This applies in particular to the fish oil from cold water fish.
Vorzugsweise verwendet man daher Fischöl von Kaltwasser fischen, insbesondere Fischöl aus dem Fleisch von Lachsen, Heringen, Salmen, Forellen, Sardellen, Makrelen und/oder Sardinen sowie Lebertran, insbesondere von Dorschen.Fish oil from cold water is therefore preferably used fish, especially fish oil from salmon meat, Herring, salmon, trout, anchovy, mackerel and / or Sardines and cod liver oil, especially from cod.
Besonders bevorzugt enthält das Fischöl 15 bis 50 Gew.-%, insbesondere 20 bis 30 Gew.-%, hochungesättigte Fettsäuren vom Omega-3-Typ. Zu derartigen Fettsäuren zählen Eico sapenteinsäure und Docosahexaensäure. Vorzugsweise setzt man Fischöl ein, das 10 bis 30 Gew.-%, insbesondere 15 bis 20 Gew.-% Eicosapentaensäure und 7 bis 20 Gew.-%, insbesondere 10 bis 15 Gew.-% Docosahexaensäure enthält.The fish oil particularly preferably contains 15 to 50% by weight, in particular 20 to 30 wt .-%, highly unsaturated fatty acids Omega-3 type. Such fatty acids include Eico sapentic acid and docosahexaenoic acid. Preferably sets one fish oil, the 10 to 30 wt .-%, in particular 15 to 20% by weight of eicosapentaenoic acid and 7 to 20% by weight, contains in particular 10 to 15 wt .-% docosahexaenoic acid.
Das Carnitin kann auch in Form eines pharmazeutisch ver träglichen Salzes, z. B. als Hydrochlond, eingesetzt werden. Das Carnitin kommt vorzugweise als L-Carnitin zur Anwendung. The carnitine can also be in the form of a pharmaceutical ver inert salt, e.g. B. can be used as hydrochloride. The carnitine is preferably used as L-carnitine.
Das Verhältnis von Fischöl zu Carnitin liegt im Bereich von 1 : 2 bis 10 : 1, vorzugsweise im Bereich von 1 : 1 bis 5 : 1.The ratio of fish oil to carnitine is in the range of 1: 2 to 10: 1, preferably in the range of 1: 1 to 5: 1.
Das erfindungsgemäße Mittel wird oral verab reicht. Geeignete Darreichungsformen sind Kapseln, Lösun gen, Dispersionen etc. Vorzugsweise wird das Mittel als Kapsel (Weich- oder Hartgelatine) verabreicht, die 500 bis 1000 mg, insbesondere 600 bis 800 mg, Fischöl und 200 bis 400 mg, insbesondere 200 bis 300 mg, Carnitin enthält. Das Mittel kann auch in zwei Teilen vorliegen, wobei die beiden Komponenten voneinander getrennt gleich zeitig oder nacheinander verabreicht werden können.The agent according to the invention is administered orally enough. Suitable dosage forms are capsules, solutions conditions, dispersions etc. The agent is preferably used as Capsule (soft or hard gelatin) administered, the 500th up to 1000 mg, especially 600 to 800 mg, fish oil and 200 to 400 mg, especially 200 to 300 mg, carnitine contains. The agent can also be in two parts, the two components being the same separately from each other can be administered early or sequentially.
Die Herstellung der erfindungsgemäßen Mittel erfolgt in üblicher Weise durch Zusammengeben oder getrennte Formulierung der beiden Komponenten, gegebenenfalls unter Verwendung üblicher Zusätze und Hilfsstoffe.The agents according to the invention are produced in the usual way by combining or separate Formulation of the two components, if necessary under Use of usual additives and auxiliary substances.
Die Dosierung des erfindungsgemäßen Mittels liegt im allgemeinen im Bereich von 1 bis 10 Gramm pro Tag bei Erwachsenen, wobei Fischöl und Carnitin in den genannten Mengenanteilen vorliegen.The dosage of the agent according to the invention is generally in the range of 1 to 10 grams per day Adults, taking fish oil and carnitine in those mentioned Quantities are available.
Das nachfolgende Beispiel erläutert die Erfindung.The following example explains the invention.
Jeweils 200 mg Carnitin werden mit jeweils 400, 500 und 600 mg Heringsöl, Sardinenöl und Lachsöl in eine Weich gelatinekapsel gefüllt.Each 200 mg of carnitine with 400, 500 and 600 mg of herring oil, sardine oil and salmon oil in a soft filled gelatin capsule.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19904012894 DE4012894C2 (en) | 1990-04-23 | 1990-04-23 | Pharmaceutical agent for the treatment of disorders of the fat metabolism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19904012894 DE4012894C2 (en) | 1990-04-23 | 1990-04-23 | Pharmaceutical agent for the treatment of disorders of the fat metabolism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE4012894A1 DE4012894A1 (en) | 1991-10-24 |
| DE4012894C2 true DE4012894C2 (en) | 1998-11-12 |
Family
ID=6404903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19904012894 Expired - Lifetime DE4012894C2 (en) | 1990-04-23 | 1990-04-23 | Pharmaceutical agent for the treatment of disorders of the fat metabolism |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE4012894C2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19503993A1 (en) * | 1995-02-08 | 1996-08-14 | Johann Friedrich Dr Med Desaga | Enteral product contg n-3-fatty acid or deriv and medium chain length tri:glyceride |
| IT1277953B1 (en) * | 1995-12-21 | 1997-11-12 | Sigma Tau Ind Farmaceuti | PHARMACEUTICAL COMPOSITION CONTAINING L-CARNITINE OR AN ALCANOYL L-CARNITINE AND A 3-OMEGA SERIES POLYUNSATURED ACID USEFUL |
| ES2208131B1 (en) * | 2002-03-27 | 2005-09-01 | Volker Bartz | METHOD FOR THE MANUFACTURE OF A LIPID LEVEL REDUCING MEDICINAL PRODUCT FOR ORAL ADMINISTRATION. |
| DE10214005A1 (en) * | 2002-03-27 | 2003-10-09 | Volker Bartz | Orally administered dietetic, nutritional supplement or medicament composition, useful as hypolipemic agent, comprising mixture of pectin and/or guar powder with eicosapentaenoic and docosahexaenoic acids |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3721137A1 (en) * | 1987-06-26 | 1989-01-05 | Dietl Hans | Fat emulsion for intravenous use |
| DE3726299A1 (en) * | 1987-06-26 | 1989-02-23 | Dietl Hans | Fat emulsion for intravenous use |
-
1990
- 1990-04-23 DE DE19904012894 patent/DE4012894C2/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3721137A1 (en) * | 1987-06-26 | 1989-01-05 | Dietl Hans | Fat emulsion for intravenous use |
| DE3726299A1 (en) * | 1987-06-26 | 1989-02-23 | Dietl Hans | Fat emulsion for intravenous use |
Non-Patent Citations (2)
| Title |
|---|
| DE-Z: WEBER, P.C. * |
| SCHACKY, v.C: HochunggesättigteFettsäuren vom w-3-Typ, Nr. 1/2, 126.Jg., 1986, S.4-7 * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE4012894A1 (en) | 1991-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT398779B (en) | FATTY ACID COMPOSITION, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT | |
| DE60000133T2 (en) | ESSENTIAL FATTY ACIDS FOR PREVENTING CARDIOVASCULAR SEASONS | |
| EP0607231B1 (en) | Use of an emulsion to prepare an intravenously administered medicament for treating skin diseases | |
| DE68905863T2 (en) | COMPOSITIONS OF ESSENTIAL FATTY ACIDS. | |
| DE68911103T2 (en) | Use of fatty acids for the treatment of myalgic encephalomyelitis. | |
| DE60212786T2 (en) | Use of polyunsaturated fatty acids for the primary prevention of cardiovascular events | |
| DE69618158T2 (en) | Pharmaceutical composition containing an alkanoyl-L-carnitine in combination with a polyunsaturated fatty acid of the omega-3 series for the prevention and treatment of disorders of the fat metabolism | |
| US20070105954A1 (en) | Formulation containing a carboxylic acid or an ester thereof | |
| EP0014910A1 (en) | Wholly acetylated monoglycerides for use for lowering of raised levels of cholesterol and/or neutral fats in human blood and process for production of pharmaceutical compositions for this purpose and dietetic foodstuffs containing them | |
| DE68917678T2 (en) | Methods and agents for the treatment of Alzheimer's disease, related dementias and epilepsy. | |
| EP0584159B1 (en) | Nutrient preparation | |
| DE19855426A1 (en) | Agents for the therapy and prophylaxis of rheumatic-arthritic diseases and for the prophylaxis of cardiovascular diseases | |
| DE69118130T2 (en) | food | |
| LU84892A1 (en) | KOMPOSITION ZUR REDUKTION DER SEBUMSEKRETION | |
| DE4012894C2 (en) | Pharmaceutical agent for the treatment of disorders of the fat metabolism | |
| EP0720481A1 (en) | Uses of vegetable oils | |
| EP0232501B1 (en) | Pharmaceutical preparation for the treatment of lipid metabolism disorders (hyperlipoproteinemia) | |
| EP0273407B1 (en) | Medicine for improving the specific properties of blood | |
| DE10214005A1 (en) | Orally administered dietetic, nutritional supplement or medicament composition, useful as hypolipemic agent, comprising mixture of pectin and/or guar powder with eicosapentaenoic and docosahexaenoic acids | |
| DE20205184U1 (en) | Blood lipid lowerers for oral use | |
| DE69822834T2 (en) | SYNERGISTIC COMPOSITIONS OF LYCOPINE AND VITAMIN E PREVENTING THE OXIDATION OF LDL | |
| EP0958828A1 (en) | Artichoke containing preparation especially for use as medicaments or nutritional supplement | |
| DE69407684T2 (en) | Use of L-carnitine or acyl-L-carnitine and valproate for the treatment of seizure disorders | |
| EP1965791B1 (en) | Novel compositions against alkyl-acyl-gpc, the derivatives and products thereof | |
| JPH01156922A (en) | Production of drug for treating brain disease and treatment compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OM8 | Search report available as to paragraph 43 lit. 1 sentence 1 patent law | ||
| 8110 | Request for examination paragraph 44 | ||
| 8127 | New person/name/address of the applicant |
Owner name: GIELSDORF, WERNER, DR., 89346 BIBERTAL, DE |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: REDINOMEDICA AG, 80538 MUENCHEN, DE |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: REDINOMEDICA AG, 33649 BIELEFELD, DE |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: SFS INTERNATIONAL LTD., CLONMEL, TIPPERARY, IE |